

H.F. 3876

As amended by H3876A2

Subject Medical cannabis program changes

Authors Edelson

Analyst Elisabeth Klarqvist

Date March 11, 2022

Overview

The commissioner of health administers the medical cannabis program, including maintaining the registry of patients who participate in the program and registering manufacturers to provide medical cannabis under the program. This bill makes a number of changes to the program, including changing a term used, requiring the commissioner to implement a medical cannabis electronic database, requiring laboratories to collect or contract for the collection of medical cannabis samples it will test, making changes related to the transportation of medical cannabis, and deleting obsolete language.

Summary

Section Description

1 Medical cannabis paraphernalia.

Amends § 152.22, subd. 8. Changes a term used in the medical cannabis statutes from medical cannabis product to medical cannabis paraphernalia.

2 Medical cannabis manufacturer registration.

Amends § 152.25, subd. 1. In a subdivision governing registration of medical cannabis manufacturers, strikes an obsolete date and instead requires a medical cannabis manufacturer, as a condition of registration, to begin supplying medical cannabis within eight months of initial registration. Requires the commissioner to implement a state-centralized medical cannabis electronic database to monitor and track medical cannabis inventories from seed or clone source through cultivation, processing, testing, and distribution or disposal. Requires manufacturers and laboratories to submit to the commissioner information needed to maintain the database.

3 Commissioner duties.

Amends § 152.27, subd. 2. In a subdivision governing duties of the commissioner for the medical cannabis program, strikes language authorizing a health care practitioner to certify that a patient is physically or developmentally disabled and requires assistance in administering or obtaining medical cannabis (a health care practitioner

Section Description

certification that a patient needs assistance in administering or obtaining medical cannabis was formerly required for a patient to obtain a registered designated caregiver, but this requirement was removed in 2021).

4 Manufacturer; requirements.

Amends § 152.29, subd. 1. Changes a term used in a subdivision governing manufacturer operations, from medical cannabis products to medical cannabis paraphernalia. Also requires a laboratory under contract with a manufacturer to collect medical cannabis samples from the manufacturer's production facility for testing, or contract with a third party other than the manufacturer to collect samples for testing. Requires the cost of collecting samples to be paid by the manufacturer.

5 Manufacturer; distribution.

Amends § 152.29, subd. 3. Changes a term used in a subdivision governing distribution of medical cannabis, from medical cannabis products to medical cannabis paraphernalia.

6 Transportation of medical cannabis; transport staffing.

Amends § 152.29, subd. 3a. Modifies a subdivision governing the transportation of medical cannabis and staffing of transport vehicles, to:

- allow medical cannabis manufacturers to contract with a third party for armored car services to deliver medical cannabis to distribution facilities;
- allow a third-party testing laboratory to staff a transport motor vehicle with one or more employees when transporting medical cannabis from a production facility to the testing laboratory;
- allow Department of Health staff to transport medical cannabis and other samples to a laboratory for testing and during special investigations if there is a potential threat to public health. Requires the transport motor vehicle to be staffed by at least two Department of Health employees; and
- allow a Tribal medical cannabis program operated by a federally recognized Indian Tribe located in Minnesota to transport samples of medical cannabis to testing laboratories in the state. Requires transport vehicles to be staffed by at least two employees of the Tribal medical cannabis program.

7 Patient duties.

Amends § 152.30. In a section establishing duties for patients registered in the medical cannabis program, changes a term used, from medical cannabis products to medical cannabis paraphernalia.

Section Description

8 Criminal and civil protections.

Amends § 152.32, subd. 2. In a subdivision establishing criminal and civil protections related to participation in the medical cannabis program, changes a term used, from medical cannabis products to medical cannabis paraphernalia.

9 Impact assessment of medical cannabis therapeutic research.

Amends § 152.36. In a section establishing a task force on medical cannabis therapeutic research and establishing duties for the task force, strikes obsolete language regarding reports, initial appointments, and the first task force meeting.



Minnesota House Research Department provides nonpartisan legislative, legal, and information services to the Minnesota House of Representatives. This document can be made available in alternative formats.

www.house.mn/hrd | 651-296-6753 | 155 State Office Building | St. Paul, MN 55155